PROPRIETARY DIMER PLATFORM TECHNOLOGY
OrphoMed leverages its proprietary platform technology to design first-in-class dimer therapeutics based on well-characterized small molecules. A key component of OrphoMed’s dimers is the linker. The linker is metabolically and chemically stable. The conformationally stable dimer inherits the receptor pharmacology of the parent molecule without its metabolic burden. These characteristics result in therapeutic candidates engineered to offer superior efficacy and safety.
Unbreakable link (chemically and metabolically stable)
Same pharmacology as the parent
Distribution profile is different from the parent